Ponvory

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

PsoriasisUlcerative Colitis (UC)

107 competitors in Psoriasis

#DrugCompanyPhaseTrials

1

Zasocitinib

Takeda

Phase 3

12

D-2570

IInventisBio Co., Ltd

Phase 3

43

TAK-279

Takeda

Phase 3

34

Ponvory

VVanda Pharmaceuticals

Phase 3

15

SYHX1901

CCSPC Ouyi Pharmaceutical Co., Ltd.

Phase 3

26

Vunakizumab (IL-17A Inhibitor)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

17

SHR-1314

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

48

ICP-488

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

39

HS-10374

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

310

IDP-118 Lotion

BBausch Health Americas, Inc.

Phase 3

8Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Multiple Sclerosis3 trials

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

Completed·Johnson & Johnson·Phase 3·NCT03232073·877 enrolled

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

Terminated·Johnson & Johnson·Phase 3·NCT02907177·136 enrolled

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

Completed·Johnson & Johnson·Phase 3·NCT02425644·1,133 enrolled

Adult1 trial

A Study of Ponesimod in Healthy Adult Participants

Completed·Johnson & Johnson·Phase 1·NCT05552196·28 enrolled

Chronic GVHD1 trial

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

Terminated·Johnson & Johnson·Phase 2·NCT02461134·1 enrolled

Female1 trial

Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects

Completed·Johnson & Johnson·Phase 1·NCT02136888·116 enrolled

Relapsing-Remitting Multiple Sclerosis1 trial

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

Completed·Johnson & Johnson·Phase 2·NCT01093326·353 enrolled

4 more indications

Oral1 trial

Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects

Completed·Johnson & Johnson·Phase 1·NCT02068235·17 enrolled

Psoriasis1 trial

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Not yet recruiting·VVanda Pharmaceuticals·Phase 3·NCT07362017·300 enrolled

Pregnancy1 trial

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Recruiting·Biogen··NCT05688436·1,178 enrolled

Ulcerative Colitis (UC)1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ponesimod in Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting·VVanda Pharmaceuticals·Phase 3·NCT07686081·150 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Patent Landscape[5]

Related News